

---

## Sprint Bioscience Q3 - Steady sales and continued progress

Sprint Bioscience delivered Q3 sales within the recent range at SEK 14.8m, mostly related to the Day One Biopharmaceuticals partner and the VADA project. The cash balance was SEK 31.7m in Q3 (36m in Q2 2024). Sprint Bioscience continues to market and attracts interest from potential partners for TREN1 (DISA), NNMT and STK25 programs, and during the quarter, Sprint Bioscience also completed the handover process for PETRA01. Our Base Case ahead is SEK 3.00 (Bull SEK 12 and Bear SEK 0.50).

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Sprint Bioscience Q3 - Steady sales and continued progress](#)